



application claims drawn to Group I identified by the Examiner (e.g., claims directed to nucleic acids, vectors, host cells, etc.). Claims 10-26 were canceled in the above amendment without prejudice, as being drawn to non-elected inventions.

The office action also set forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. In accordance with the requirements of 37 CFR Sections 1.821-1.825, Applicants are providing herewith a substitute paper copy of the Sequence Listing, along with a computer readable form of the Sequence Listing. The sequence disclosures in the Sequence Listing are fully supported by the specification as filed, and as such, do not introduce new matter. It is believed that the substitute Sequence Listing corrects the defects noted in the Notice to Comply. Entry of the Sequence Listing into the present specification is respectfully requested.

Respectfully Submitted  
GENENTECH, INC.

Date: March 7, 2000

By: Diane L. Marschang  
Diane L. Marschang  
Reg. No. 35,600

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-5416  
Fax: (650) 952-9881